IP Library › Granted Patent US 12,486,333
Granted Patent B2
US 12,486,333 · App. 17/292,883 · Granted Dec 2, 2025

Tissue plasminogen activator antibodies and method of use thereof

Inventors: James Carl Keith, Jr. (Andover, MA); Alexander Noel Fraser Brown (Stevenage, GB); Preeti Bakrania (Stevenage, GB)
Assignee: EMSTOPA LIMITED
C07K16/40A61P7/02A61K2039/505C07K2317/24C07K2317/76C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,486,333
App. No.
17/292,883
Granted
Dec 2, 2025
Kind
B2
Abstract

The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction.

Claims (28)

1 . An antibody molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant to inhibit degradation of human fibrin clots, wherein the antibody has sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, and wherein the amino acid sequence of said TPA mutant has at least 65% identity to SEQ ID NO: 1 or SEQ ID NO: 2; wherein the antibody comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 3 or 4, a CDR2 of SEQ ID NO: 5 or 6, and a CDR3 of SEQ ID NO: 7 or 8, and a light chain variable domain with a CDR1 of SEQ ID NO: 9 or 10, a CDR2 of SEQ ID NO: 11 or 12, and a CDR3 of SEQ ID NO: 13, wherein the antibody molecule is a humanized antibody or an antigen binding fragment of a humanized antibody.

2 . The antibody molecule of claim 1 which comprises a heavy chain variable domain with a CDR1 of SEQ ID NO: 3, a CDR2 of SEQ ID NO: 5, and a CDR3 of SEQ ID NO: 7, and a light chain variable domain with a CDR1 of SEQ ID NO: 9, and a CDR2 of SEQ ID NO: 11.

3 . The antibody molecule of claim 1 which comprises a heavy chain variable domain selected from SEQ ID NOs: 14 to 28 and a light chain variable domain of SEQ ID NO: 29 or 30.

4 . The antibody molecule of claim 3 which comprises a heavy chain variable domain selected from SEQ ID NOs: 14 to 28, and a light chain variable domain of SEQ ID NO: 29.

5 . The antibody molecule of claim 3 which comprises a heavy chain variable domain of SEQ ID NO: 14, and a light chain variable domain of SEQ ID No: 29, or a heavy chain variable domain of SEQ ID NO: 15, and a light chain variable domain of SEQ ID No: 29, or a heavy chain variable domain of SEQ ID NO: 14, and a light chain variable domain of SEQ ID No: 30, or a heavy chain variable domain of SEQ ID NO: 15, and a light chain variable domain of SEQ ID No: 30.

6 . The antibody molecule of claim 1 , wherein the humanized antibody or antigen binding fragment of a humanized antibody is a Fab, Fab′, or F(ab′)2 fragment or a single chain antibody (ScFv).

7 . The antibody molecule of claim 6 , wherein the humanized antibody or antigen binding fragment of a humanized antibody is a Fab, Fab′, or F(ab′)2 fragment.

8 . The antibody molecule of claim 6 which is a scFv, wherein the heavy chain variable domain and the light chain variable domain are linked to each other through a linker peptide of SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, or SEQ ID NO: 37.

9 . The antibody molecule of claim 8 which comprises SEQ ID NO: 38, or SEQ ID NO:39.

10 . The antibody molecule of claim 6 having a heavy chain comprising SEQ ID NO: 40 or SEQ ID NO: 41, and a light chain comprising SEQ ID NO: 42.

11 . The antibody of claim 6 which is a Fab molecule having a Fd fragment comprising SEQ ID NO: 31 or SEQ ID NO: 32, and a light chain comprising SEQ ID NO: 33.

12 . A pharmaceutical composition comprising an antibody molecule of claim 1 and a pharmaceutically acceptable carrier.

13 . A method of treatment of TPA induced hemorrhage or systemic hemorrhage after TPA treatment, the method comprising administering an effective amount of an antibody molecule of claim 1 to a subject in need thereof.

14 . A method of manufacturing an antibody molecule of claim 1 , comprising:

(a) providing a host cell comprising one or more nucleic acids encoding said antibody molecule in functional association with an expression control sequence,

(b) culturing said host cell, and

(c) recovering the antibody molecule from the cell culture.

15 . A kit comprising an antibody of claim 1 , or a pharmaceutical composition thereof.

16 . The kit according to claim 15 , comprising a human tissue plasminogen activator (TPA) or a TPA mutant wherein the amino acid sequence of said TPA mutant has at least 65% identity to SEQ ID NO: 1 or SEQ ID NO: 2.

17 . The kit according to claim 16 , wherein the human tissue plasminogen activator (TPA) or TPA mutant is alteplase, reteplase or tenecteplase.

18 . The kit according to claim 17 comprising:

(a) a pharmaceutical composition comprising human tissue plasminogen activator (TPA) or TPA mutant selected from alteplase, reteplase and tenecteplase;

(b) a container; and

(c) a label.

19 . A kit according to claim 17 comprising:

(a) a first pharmaceutical composition comprising human tissue plasminogen activator (TPA) or TPA mutant selected from alteplase, reteplase and tenecteplase;

(b) a second pharmaceutical composition comprising the antibody; and

(c) instructions for separate administration of the first and second pharmaceutical compositions to a subject, wherein the first and second pharmaceutical compositions are contained in separate containers and the second pharmaceutical composition is administered to a subject requiring treatment or prevention of systemic haemorrhage after TPA treatment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2021
From: KEITH, JAMES CARL, JR.; BROWN, ALEXANDER NOEL FRASER; BAKRANIA, PREETI
To: EMSTOPA LIMITED
Reel/Frame 058513/0916 →
Priority Claims (1)
GB 1818477 · Nov 13, 2018 · national
Continuity (1)
Related Publication 20210395393A1 · Dec 23, 2021
References Cited (61)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 20150353647A1 · Reed · 2015 [cited by applicant]
WO WO8801649A1 · 1988 [cited by applicant]
WO WO9005144A1 · 1990 [cited by applicant]
WO WO9117271A1 · 1991 [cited by applicant]
WO WO9404678A1 · 1994 [cited by applicant]
WO WO9413804A1 · 1994 [cited by applicant]
WO WO9429348A2 · 1994 [cited by applicant]
WO WO9825971A1 · 1998 [cited by applicant]
WO WO9848837A1 · 1998 [cited by applicant]
WO WO0179258A1 · 2001 [cited by applicant]
WO WO02056910A1 · 2002 [cited by applicant]
WO WO03050531A2 · 2003 [cited by applicant]
WO WO2004003019A2 · 2004 [cited by applicant]
WO WO2004041865A2 · 2004 [cited by applicant]
WO WO2004081026A2 · 2004 [cited by applicant]
WO WO2014116706A1 · 2014 [cited by applicant]
Barber et al., “D-Dimer Predicts Early Clinical Progression in Ischemic Stroke: Confirmation Using Routine Clinical Assays,” [cited by applicant]
Burtet et al., “Production of a Recombinant Fab in Pichia pastoris from a Monocistronic Expression Vector,” J. Biochem 142(6): 665-669 (2007). [cited by applicant]
Cajot et al., “Monoclonal antibodies directed against human tissue-type plasminogen activator: a characterization of their species specificity, affinity and heavy-chain binding,” [cited by applicant]
Cardenas et al., “Elevated Tissue Plasminogen Activator and Reduced Plasminogen Activator Inhibitor Promote Hyperfibrinolysis in Trauma Patients,” [cited by applicant]
Carmen et al., “Concepts in antibody phage display,” Briefings in Functional Genomics and Proteomics 1(2): 189-203 (2002). [cited by applicant]
Chapman et al., “Overwhelming tPA Release, not PAI-1 Degradation, is Responsible for Hyperfibrinolysis in Severely Injured Trauma Patients,” [cited by applicant]
Database Medline, US National Library of Medicine, Ball et al., “Selection of monoclonal antibodies that bind and inhibit tissue-type plasminogen activator,” Accession No. NLM8359825 (1993). [cited by applicant]
Donnan et al., “How to make better use of thrombolytic therapy in acute ischemic stroke,” [cited by applicant]
Duque et al., “Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review,” [cited by applicant]
Fergusson et al., “A comparison of aprotinin and lysine analogues in high-risk cardiac surgery,” [cited by applicant]
Gebhardt et al., “Fibrinolysis in patients with mild-to-moderate bleeding tendency or unknown cause,” [cited by applicant]
Holliger et al., “Diabodies: small bivalent and bispecific antibody fragments,” [cited by applicant]
Huston et al., “Medical Applications of Single-Chain Antibodies,” International Reviews of Immunology 10(2-3): 195-217 (1993). [cited by applicant]
Khan et al., “Severely Injured Trauma Patients With Admission Hyperfibrinolysis; Is There a Role of Tranexemic Acid? Findings From the PROPPR Trial,” [cited by applicant]
Kizhedath et al., “Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope,” [cited by applicant]
Knappik et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,” [cited by applicant]
Leiper et al., “Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease,” [cited by applicant]
Longstaff et al., “A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units,” [cited by applicant]
Manji et al., “Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors,” [cited by applicant]
Matsuo et al., “Monoclonal antibody to human tissue plasminogen activator,” [cited by applicant]
Morgenstern et al., “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,” [cited by applicant]
Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,” [cited by applicant]
Munoz et al., “Is ε-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? A Meta-Analysis,” [cited by applicant]
Nelson et al., “Demystified: Monoclonal antibodies,” [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” [cited by applicant]
Rippmann et al., “Procaryotic Expression of Single-Chain Variable-Fragment (scFv) Antibodies: Secretion in L-Form Cells of Proteus mirabilis Leads to Active Product and Overcomes the Limitations of Periplasmic Expressio… [cited by applicant]
Rønning et al., “Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale,” [cited by applicant]
Saver, “Hemorrhage After Thrombolytic Therapy for Stroke. The Clinically Relevant Number Needed to Harm,” [cited by applicant]
Sazonova et al., “Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator,” [cited by applicant]
Su et al., “Activation of PDGF-CC by Tissue Plasminogen Activator Impairs Blood Brain Barrier Integrity During Ischemic Stroke,” [cited by applicant]
Swanson et al., “A Semiautomated Method for Measuring Brain Infarct Volume,” [cited by applicant]
World Health Organization, Expert Committee on Biological Standardization (WHO/BS/07.2068), Geneva, Oct. 8-12, 2007 (37 pgs.). [cited by applicant]
Willems et al., “Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives,” [cited by applicant]
Xu et al., “Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials,” [cited by applicant]
European Patent Office, International Search Report in International Application No. PCT/EP2019/081225 (Mar. 9, 2020). [cited by applicant]
European Patent Office, Written Opinion in International Application No. PCT/EP2019/081225 (Mar. 9, 2020). [cited by applicant]
International Bureau of WIPO, International Preliminary Report on Patentability in International Application No. PCT/EP2019/081225 (May 18, 2021). [cited by applicant]
Ball et al., “Selection of monoclonal antibodies that bind and inhibit tissue-type plasminogen activator,” [cited by applicant]
Bayes-Genis et al., “D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain,” [cited by applicant]
Eberle et al., “Clinical update on thrombolytic use in pulmonary embolism: A focus on intermediate-risk patients,” [cited by applicant]
Gupta et al., “Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children,” [cited by applicant]
Gurwitz et al., “Risk for intracranial haemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2,” [cited by applicant]
James et al., “Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis,” [cited by applicant]